866-997-4948(US-Canada Toll Free)

Smoking Addiction - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 86 Pages

Smoking Addiction - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides an overview of the Smoking Addiction (Central Nervous System) pipeline landscape.

In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 8, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Smoking Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Smoking Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Smoking Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Smoking Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smoking Addiction - Overview
Smoking Addiction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Smoking Addiction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smoking Addiction - Companies Involved in Therapeutics Development
Aradigm Corp
Bionex Pharmaceuticals LLC
Bioprojet SCR
CoMentis Inc
Embera NeuroTherapeutics Inc
Invion Ltd
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
Lotus Pharmaceutical Co Ltd
NAL Pharmaceuticals Ltd
Pfizer Inc
Rock Creek Pharmaceuticals, Inc.
Selecta Biosciences Inc
Sopharma AD
Zynerba Pharmaceuticals Inc
Smoking Addiction - Drug Profiles
(metyrapone + oxazepam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKR-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amitifadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anatabine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-1.4979 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytisine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTS-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JLP-1603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-39393406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nadolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NFL-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIC-7DT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nicotine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nicotine bitartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nicotine bitartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06413367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-068 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URB-694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Smoking Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smoking Addiction - Dormant Projects
Smoking Addiction - Discontinued Products
Smoking Addiction - Product Development Milestones
Featured News & Press Releases
May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention
Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")
Oct 20, 2016: OWC Pharmaceutical Research Completes Development of Its Medical Cannabis Sublingual Tablet
Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis
Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation
Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation
Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation
Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation
Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform
Jan 29, 2014: FDA clears path for Smoking Cessation clinical trial of INV102 (nadolol)
Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs
Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint
Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Smoking Addiction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Smoking Addiction - Pipeline by Aradigm Corp, H1 2017
Smoking Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2017
Smoking Addiction - Pipeline by Bioprojet SCR, H1 2017
Smoking Addiction - Pipeline by CoMentis Inc, H1 2017
Smoking Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2017
Smoking Addiction - Pipeline by Invion Ltd, H1 2017
Smoking Addiction - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
Smoking Addiction - Pipeline by Johnson & Johnson, H1 2017
Smoking Addiction - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
Smoking Addiction - Pipeline by Pfizer Inc, H1 2017
Smoking Addiction - Pipeline by Rock Creek Pharmaceuticals, Inc., H1 2017
Smoking Addiction - Pipeline by Selecta Biosciences Inc, H1 2017
Smoking Addiction - Pipeline by Sopharma AD, H1 2017
Smoking Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
Smoking Addiction - Dormant Projects, H1 2017
Smoking Addiction - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Smoking Addiction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *